Company Filing History:
2 out of 6 
1 out of 11 Years Active: 2016-2017
Title: Innovations by Masahiro Tomita: Revolutionizing Antibody Production
Introduction
Masahiro Tomita, an accomplished inventor from Fujioka, Japan, has made significant strides in the field of biotechnology with his innovative methods for antibody production. Holding two patents, his work focuses on enhancing the safety and efficiency of glycan-hydrolyzed antibodies and transgenic silkworms for fibrinogen production.
Latest Patents
Tomita's latest patents include a groundbreaking method for preparing glycan-hydrolyzed antibodies and a novel approach for producing fibrinogen using transgenic silkworms. The first patent provides a method for creating an acceptor that is either an N-glycan hydrolyzed antibody or an Fc fragment, aimed at generating antibodies with a homogeneous N-glycan structure. It details processes for determining suitable endoglycosidases for the preparation and measuring N-glycans linked to antibodies.
The second patent introduces a transgenic silkworm designed to produce fibrinogen at a low cost while ensuring high safety. It allows the expression of fibrinogen subunits in the silk gland cells, enabling the mass production of functional fibrinogen within the cocoon filament. This innovative approach has the potential to dramatically lower production costs while maintaining essential coagulation activity.
Career Highlights
Throughout his career, Masahiro Tomita has been associated with notable organizations such as Immuno-biological Laboratories Co., Ltd. and The Noguchi Institute. His contributions in these roles have propelled research in antibody development and biotechnology forward, establishing him as a key figure in the industry.
Collaborations
Tomita has worked with talented colleagues such as Takashi Shirai and Masako Mori, showcasing a collaborative spirit that strengthens his innovative efforts. Their collective expertise has undoubtedly contributed to the successful development of his patented technologies.
Conclusion
Masahiro Tomita's inventive methods in biotechnology represent noteworthy advancements in the production of antibodies and fibrinogen. His patented initiatives not only enhance the efficacy of antibody preparations but also pave the way for cost-effective solutions in biopharmaceuticals. As innovations like those from Tomita continue to emerge, they hold the promise of transforming the landscape of medical therapeutics.